Many TikTok users are now falsely diagnosing themselves with rare mental disorders. (Wall Street Journal)
Older folks struggled with mental health during the COVID pandemic, with women and single people seeing the greatest declines. (JAMA Psychiatry)
According to a systematic review of 83 reports, there was evidence supporting ketamine as a “robust, rapid and transient” antidepressant. “It’s important to note that this review examined ketamine administration in carefully controlled clinical settings where any risks of ketamine can be safely managed,” said co-author Ozden Merve Mollaahmetoglu, MSc, of the University of Exeter in England, in a statement. (British Journal of Psychiatry Open)
Sandoz announced it launched a generic version of naloxone hydrochloride (Narcan) nasal spray 4 mg to reverse opioid overdose.
Merck skirted a lawsuit from a Wisconsin boy who allegedly developed serious psychiatric issues after taking the asthma drug montelukast, the generic version of Singulair. In March 2020, the FDA added a boxed warning to the label regarding suicidality in patients. (Bloomberg Law)
FitBit filed a new patent for technology that could screen wearers for depression and bipolar disorder. (Wareable)
In other patent news, Mindset Pharma announced it filed an international patent application for its family 3 novel psychedelic compounds in development for certain psychiatric and neurological conditions, such as ADHD and Alzheimer’s disease.
Actor James Franco recently opened up about his struggles with sex addiction after being sued by students of his acting school for alleged sexual exploitation. (Reuters)
Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.